We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Sensor Technology May Improve Cancer Diagnosis

By LabMedica International staff writers
Posted on 19 Jun 2017
Researchers have developed a plasmonic sensor that could provide reliable early detection of biomarkers for many forms of cancer and eventually for other diseases. More...
The sensor detected cancer biomarker carcinoembryonic antigen (CEA) to the magnitude of only 1 nanogram/milliliter.

The research team, from University of Illinois at Urbana–Champaign (Urbana–Champaign, IL, USA), was led by Logan Liu and Lynford Goddard, associate professors of electrical and computer engineering, with students Abid Ameen and Lisa Hackett carrying out the project.

Most humans carry CEA with an average range of 3-5 nanograms/milliliter. The researchers chose to focus on CEA because its presence in higher concentrations is an early indicator of many forms of cancer, including lung and prostate cancers.

The plasmonic sensor is an improvement of the current method. First, it improved the limit of detection by at least 2 orders of magnitude. Secondly, it works with much less instrumentation so it is less expensive and more portable, and doesn’t require nearly the expertise. Also, only a small amount of blood sample is required, such as from a simple finger prick.

“By combining plasmonic properties and the optical cavity properties together in one device we are able to detect lower concentration of biomarker by light confinement and transmission in the cavity layer and from the top of the device, respectively, based on the thickness of the multilayers and the refractive index of the cavity layer,” Ameen explained.

“The nanocup array provides extraordinary optical transmission,” Hackett added, “If you take a thin metal film and try to shine light through it, there will be almost no light transmitted. However if you put a periodic array of nanoholes, or in our case a nanocup structure, then what you see is a resonance condition where at a certain wavelength, you will have a peak in the transmission through this device.”

“Usually when you have these types of refractometric plasmonic sensors, you have a shift in the angle or a change in your wavelength when the resonance condition is met,” said Hackett, “In our case, because we have incorporated a nanocavity, we have a fixed resonance wavelength.” As the concentration of biomolecules (in this case CEA) increases, so does the refractive index, which produces an increase of the transmission intensity at a fixed wavelength that can be easily detected.

Eventually “we can take this sensor, which we’ve optimized and incorporated with an LED and have the most compact instrumentation, in fact no sophisticated instrumentation at all,” Ameen said.

Currently, detection methods for cancer biomarkers are implemented in high-risk patients, especially cancer patients in remission. Because of the portability and inexpensive nature of this method, it can be more easily administered to any patient at routine check-ups.

“Right now cancer is detected closer to end-stage,” Ameen noted, “We want to detect it as early as possible.” This could allow patients to be treated even before cancer cells metastasize. Down the road, the method could be used for detection of other diseases. And if “made very cost-effective and portable,” said Hackett, “it would be great to see people be able to take more control over their health and monitor something like this on their own.”

The study, by Ameen A et al, was first published March 29, 2017, in the journal Advanced Optical Materials.

Related Links:
University of Illinois at Urbana–Champaign


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
HbA1c Test
HbA1c Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.